Phase 2 Brain Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed before surgery with a suspected first-time brain tumour known as a low or high grade glioma (including types such as astrocytoma, oligodendroglioma, mixed oligo-astrocytoma, anaplastic astrocytoma, or glioblastoma multiforme)
- People whose tumour has been assessed by doctors as suitable for open brain surgery based on pre-surgery scans and imaging
- People who are able to give informed consent themselves, or who have a legally authorised representative who can do so on their behalf
- People who do not have a serious psychiatric illness
- People who are 21 years of age or older
Who may not be able to join:
- Women who are pregnant or currently breastfeeding
- People who have had an allergic reaction to fluorescein (a type of dye) in the past
- People with a history of skin conditions made worse by light, such as porphyria, photodermatosis, or exfoliative dermatitis, or a known sensitivity to porphyrins
- People who have had liver disease within the last 12 months
- People whose liver function blood test results, taken within 30 days before surgery, are more than 2.5 times above the normal range
- People whose kidney function blood test results, taken within 30 days before surgery, show creatinine levels above a certain threshold (confirm with trial site)
- People who would be unable to follow the required precautions around light sensitivity during the study
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Fluorescein performance as an intraoperative biomarker for tumor tissue will be reported.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.